IPSEN, OOO
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1929-01-01
- Employees
- 5.7K
- Market Cap
- $9.8B
- Website
- https://www.ipsen.com/
Clinical Trials
273
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (164 trials with phase data)• Click on a phase to view related trials
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
- Conditions
- Primary Biliary Cholangitis
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT07049887
A study of IPN10200 for the treatment of cervical dystonia in adults
- Conditions
- Cervical Dystonia
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Ipsen Innovation
- Target Recruit Count
- 91
- Registration Number
- 2024-519248-34-00
- Locations
- 🇺🇸
University of Arizona Health Sciences - Neurology, Tucson, Arizona, United States
🇺🇸Parkinson's Ds & Mvt Disorders Cntr, Boca Raton, Florida, United States
🇺🇸USF Health Byrd Alzheimer's Institute, Tampa, Florida, United States
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
- First Posted Date
- 2025-04-03
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 32
- Registration Number
- NCT06908954
- Locations
- 🇺🇸
ERG - Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation/Texas Liver Institute, San Antonio, Texas, United States
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
- Conditions
- Alagille Syndrome
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 30
- Registration Number
- NCT06850038
- Locations
- 🇺🇸
Proactive El Paso,LLC, El Paso, Texas, United States
🇺🇸NYU Langone - NYU Grossman School of Medicine, New York, New York, United States
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 85
- Registration Number
- NCT06833008
- Locations
- 🇺🇸
START Mid-West, Grand Rapids, Michigan, United States
🇺🇸Sarah Cannon Research Institute (SCRI) - Nashville, Nashville, Tennessee, United States
🇺🇸Mary Crowley Cancer Research Centers - Medical City Hospital - Dallas, Dallas, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 55
- Next
News
Merck KGaA Partners with Skyhawk Therapeutics in $2 Billion RNA Splicing Collaboration for Neurological Disorders
Merck KGaA, Darmstadt, Germany has entered a strategic collaboration with Skyhawk Therapeutics valued at over $2 billion to discover novel RNA-targeting small molecules for neurological disorders with high unmet medical need.
Day One Biopharmaceuticals Reports 310% Revenue Surge for Pediatric Cancer Drug OJEMDA
Day One Biopharmaceuticals reported OJEMDA net product revenue of $33.6 million in Q2 2025, representing a 310% year-over-year increase driven by expanding adoption among pediatric oncologists.
IRIC and Ipsen Initiate Phase 1 Trial of RAF Inhibitor IPN01195 for Solid Tumors
IRIC and IRICoR announced the start of a Phase 1 clinical trial for IPN01195, a RAF inhibitor small molecule therapy for solid tumors licensed to Ipsen in July 2025.
NAPOLI 3 Post-Hoc Analysis Identifies Characteristics Associated with Long-Term Survival in Metastatic Pancreatic Cancer
A post-hoc analysis of the Phase III NAPOLI 3 trial identified characteristics associated with long-term survival in metastatic pancreatic adenocarcinoma patients treated with the NALIRIFOX regimen.
World ADC San Diego Conference Highlights Growing Industry Focus on Antibody-Drug Conjugates
The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.
GENFIT Reports Strong 2024 Financial Results with First Commercial Revenues from Iqirvo®
GENFIT reported a net profit of €1.5 million for 2024, driven by €67.0 million in revenues including a €48.7 million milestone payment and royalties from Iqirvo® (elafibranor) sales in PBC.
Ipsen's Elafibranor Shows Promise in Phase II Trial for Primary Sclerosing Cholangitis
Elafibranor demonstrated a favorable safety profile and significant dose-dependent efficacy in the Phase II ELMWOOD trial for primary sclerosing cholangitis (PSC), a rare liver disease with no currently approved treatments.
Ipsen Secures Dual CHMP Approvals for Rare Liver Disease Treatments Following Regulatory Strategy Shift
Ipsen received CHMP approval for odevixibat under the new brand name Kayfanda for Alagille syndrome, marking the second approval for the same drug after rebranding due to orphan status complications.
China's NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant Follicular Lymphoma
China's National Medical Products Administration (NMPA) has granted conditional approval to tazemetostat (Tazverik) for adult patients with relapsed or refractory EZH2-mutated follicular lymphoma who have received at least two prior systemic therapies.
China Grants Conditional Approval for Tazverik to Treat Relapsed or Refractory Follicular Lymphoma
China's National Medical Products Administration (NMPA) has conditionally approved Tazverik (tazemetostat) for adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation who have received at least two prior systemic therapies.